These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 5608914

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Problems of the myeloproliferative syndrome from the pathologist's viewpoint].
    Werner W.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1969; 91(2):227-34. PubMed ID: 4184585
    [No Abstract] [Full Text] [Related]

  • 4. [Uses of ultrastructural research in the study of thrombocythemias].
    Jean G, Marx R, Gautier A.
    Nouv Rev Fr Hematol; 1966; 6(5):591-610. PubMed ID: 4226350
    [No Abstract] [Full Text] [Related]

  • 5. [Histology of bone marrow in Vaquez's disease and the problem of myelosclerosis. 70 biopsies].
    Duhamel G, Najman A, André R.
    Nouv Rev Fr Hematol; 1970; 10(2):209-22. PubMed ID: 4246273
    [No Abstract] [Full Text] [Related]

  • 6. [Atypical myeloproliferative disorders: a study on 3 cases showing pancytopenia, marrow fibrosis and the absence of splenomegaly].
    Yoshida Y, Yamagishi M, Fukuhara S, Sawada H, Ohkuma M, Uchino H, Nakamura T.
    Rinsho Ketsueki; 1984 Mar; 25(3):383-92. PubMed ID: 6471435
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [LAT (linker for activation of T cells): a useful marker for megakaryocyte evaluation on bone marrow biopsies].
    Ungari M, Pellegrini W, Borlenghi E, Marocolo D, Ubiali A, Agazzi C, Pich A, Franco V, Facchetti F.
    Pathologica; 2002 Dec; 94(6):325-30. PubMed ID: 12540999
    [Abstract] [Full Text] [Related]

  • 10. [HISTOLOGICAL CHARACTERISTICS OF THE BONE MARROW IN MYELOID SPLENOMEGALY].
    CHOME J, BOIRON M, TANZER, RIPAULT J, JACQUILLAT C.
    Arch Anat Pathol (Paris); 1964 Mar; 12():A58-61. PubMed ID: 14165482
    [No Abstract] [Full Text] [Related]

  • 11. [Clinical studies on the PAS reaction of megakaryocytes].
    Furusawa S.
    Nihon Ketsueki Gakkai Zasshi; 1968 Apr; 31(2):232-41. PubMed ID: 4180436
    [No Abstract] [Full Text] [Related]

  • 12. [On injuries to the immature forms of the megakaryocytic cell series].
    Kissóczy S, Sterbová S.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1966 Apr; 86(3):259-71. PubMed ID: 4168605
    [No Abstract] [Full Text] [Related]

  • 13. [Myeloproliferative disorders].
    Hartwich G, Lutz H.
    Med Klin; 1972 Feb 11; 67(6):183-9. PubMed ID: 4503295
    [No Abstract] [Full Text] [Related]

  • 14. Histologic criteria for classification and differential diagnosis of chronic myeloproliferative disorders.
    Frisch B, Bartl R, Burkhardt R, Jäger K.
    Haematologia (Budap); 1984 Feb 11; 17(2):209-26. PubMed ID: 6534829
    [Abstract] [Full Text] [Related]

  • 15. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
    Rudzki Z, Papla B, Stachura J.
    Pol J Pathol; 2004 Feb 11; 55(1):13-23. PubMed ID: 15195702
    [Abstract] [Full Text] [Related]

  • 16. [Splenectomy for splenomegaly of more than 1000 grams. A retrospective study of 36 patients].
    Glehen O, Caillot JL, François Y, Peyrat P, Sadeghi Loyeeh B, Griot JB, Gilly FN, Vignal J.
    Ann Chir; 1997 Feb 11; 51(10):1099-105. PubMed ID: 10868032
    [Abstract] [Full Text] [Related]

  • 17. [MEGAKARYOCYTIC SPLENOMEGALY AND CONCOMITANT HEPATIC CIRRHOSIS IN RELATION TO THE PROBLEMS OF SO-CALLED MEGAKARYOCYTIC LEUKOSIS].
    BONDI R, MARCHI F.
    Arch De Vecchi Anat Patol; 1963 Oct 11; 41():157-80. PubMed ID: 14215144
    [No Abstract] [Full Text] [Related]

  • 18. [Chronic myeloproliferative diseases].
    Verh Dtsch Ges Pathol; 1983 Oct 11; 67():214-75. PubMed ID: 6666266
    [No Abstract] [Full Text] [Related]

  • 19. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O, Loch G, Schade U, von Wasielewski R, Schlué J, Kreipe H.
    J Pathol; 2005 Apr 11; 205(5):548-57. PubMed ID: 15726648
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.